Targeted treatment with osimertinib in the adjuvant treatment of a patient with non‐small cell lung cancer – case report

Abstract

Osimertinib belongs to the tyrosine kinase inhibitors of the 3rd generation, highly effective also in the area of the central nervous system. The treatment is reserved for patients with a positive mutation of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer.

It is currently reimbursed for patients with advanced or generalized disease, however, it also proved effective in the adjuvant phase, as evidenced by our case report.